Relapsing-remitting Multiple Sclerosis Clinical Trial
Official title:
Effects of Sensori-motor Integration Balance Training on Balance Disturbances in Patients With Multiple Sclerosis
Balance impairment is a common and very disabling disturbance in people with Multiple Sclerosis. The efficacy of pharmacotherapy in treating balance impairment in MS is poorly documented in literature. Although literature dealing with the rehabilitation of balance impairment in MS is very scant, the preliminary data reports show very promising results. The present project could have a positive impact on balance and gait ability, disability, fear of falling, risk of falls and quality of life of patients with Multiple Sclerosis.
Balance impairment is one of the primary causes of disability in people with multiple
sclerosis (MS). It increases the risk of falls and contributes to the development of fear of
falling (FOF), a vicious cycle that leads to a limitation in daily life activities. The
imbalance could be caused by motor and sensorial deficits as well as sensory-motor
integration deficits. Despite the disability that balance disorders cause, literature about
its' rehabilitation is very scant. To our knowledge two studies have been published on MS
balance rehabilitation. The first paper described case reports on MS balance rehabilitation
using the "Bobath" approach. The second paper performed a preliminary randomized controlled
study describing the effectiveness in restoring balance control and reducing risk of falling
using a specific training program aimed at improving sensory-motor integration in people
with MS. Considering the several limitations of this study, further trials are warranted to
assess the usefulness of specific sensory-motor training on balance impairment in people
with MS. The aim of this randomised controlled double blinded clinical trial is to evaluate
whether a training program consisting of exercises performed under different sensory
conflict conditions can lead to an improvement in postural stability in patients with MS.
This in turn might lead to an improvement in walking ability, autonomy in daily life
activities and quality of life in people with MS.
The study will include 80 patients (age<65 years) with a diagnosis of MS relapsing remitted
according to the McDonald criteria and with an Expanded Disability Status Scale scoreā¤6.0.
Patients will be divided into 2 groups, according to a randomization design. The
experimental group will undergo a specific training program aimed at increasing balance
ability in several sensory conflict conditions. The training program will consist of fifteen
50-minute sessions over a 5 week period (3 sessions/week). The control group will undergo
conventional neurorehabilitation treatment following the same pattern of sessions as the
study group. At recruitment, after treatment (5 weeks) and in the follow-up (1 month), each
patient will be tested with the following clinical and instrumental procedures: Berg Balance
Scale, Activities-specific Balance Confidence Scale, Fatigue Severity Scale, Postural
Transfers evaluation, Multiple Sclerosis Quality Of Life (MSQOL)-54 instrument, Sensory
Organization Test, GAITRite® System and platform stabilometry.
Data will be examined at first reassessment for between group differences. Data from the
second reassessment will be analysed for within group differences. Sample characteristics
will be summarised using descriptive statistics. Due to the small sample size,
non-parametric tests will be applied: Wilcoxon's signed ranks test for within group
comparisons and the Mann-withney U test for between group comparisons, both with
significance set at p=0.05. Data will be analysed using SPSS v16 software.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02549703 -
Mitochondrial Dysfunction and Disease Progression
|
||
| Terminated |
NCT02222948 -
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT02293967 -
Mass Balance Study of MT-1303
|
Phase 1 | |
| Terminated |
NCT01790269 -
Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod
|
||
| Terminated |
NCT01701856 -
Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis
|
Phase 4 | |
| Completed |
NCT00525668 -
Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)
|
Phase 1/Phase 2 | |
| Terminated |
NCT00398528 -
An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis
|
Phase 4 | |
| Completed |
NCT00315367 -
A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties
|
Phase 4 | |
| Terminated |
NCT04032171 -
Study of Evobrutinib in Participants With RMS
|
Phase 3 | |
| Completed |
NCT01930708 -
A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
|
Phase 4 | |
| Completed |
NCT03000647 -
Guided Versus Non-guided Pelvic Floor Exercises for Urinary Incontinence in Relapsing-Remitting Multiple Sclerosis
|
N/A | |
| Completed |
NCT02205489 -
Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA
|
Phase 4 | |
| Completed |
NCT02753088 -
Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis
|
Phase 3 | |
| Recruiting |
NCT01466114 -
Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
|
Phase 2 | |
| Completed |
NCT01244139 -
Safety Study of BIIB033 in Subjects With Multiple Sclerosis
|
Phase 1 | |
| Completed |
NCT01416155 -
Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT00559702 -
Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
|
Phase 1 | |
| Completed |
NCT00493116 -
Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta
|
Phase 4 | |
| Terminated |
NCT01706107 -
Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
|
||
| Completed |
NCT01943526 -
Ireland Natalizumab (TYSABRI) Observational Program
|